All News

abstract

New JAK inhibitors in the axSpA treatment landscape

Mrinalini Dey, MD

At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.

Read Article
psA.fil_.Hands_.jpg

What’s New in Psoriatic Arthritis: A Whirlwind Tour

Jiha Lee, MD

At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.

Read Article
light bulb idea

Three Abstracts That May Shape the Future of RA Treatment

Aurelie Najm, MD, PhD

Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.

Read Article
change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq

Links:

Jiha Lee JihaRheum ( View Tweet)

CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a

Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Progress of biologics/targeted therapy in SLE We are in a transformative era for SLE, for clinicians and patients. Four targeted therapies are now licensed: belimumab (nephritis and non‑renal), voclosporin and obinutuzumab (nephritis), and anifrolumab (non‑renal). Many agents https://t.co/BuFCmj1hQd
Dr. John Cush RheumNow ( View Tweet)

🔥 TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: ✅ Primary endpoint (ACR50 + ≥10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) ✅ ACR50: 33.5% vs. 20.4% ✅ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

DR JOHN STONE gives Overview Of #IgG4 New non B cell depleter #obexelimab N=194 in RCT To add to B cell depletion w #Inebilizumab Off label but used also #Rituximab #steroids #Immunesuppressives Other investigational drugs Ex #JAKi #EULAR2026 @RheumNow #OP018 #RULARbest https://t.co/Y4saGYcdww

Links:

Janet Pope Janetbirdope ( View Tweet)
💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA? Phase 3 RCT (n=304): ASAS40 39.7% vs 24.8% placebo at week 12 with sustained benefit at week 24 #OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

Links:

sheila RHEUMarampa ( View Tweet)
COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach), Non peptide based (can be given anytime). Know about s/e and contraindications. May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar. #EULAR2026 @RheumNow https://t.co/KNudYN29PT

Links:

Bella Mehta bella_mehta ( View Tweet)
#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×